Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Mosele, Fernanda; Deluche, Elise; Lusque, Amelie; Le Bescond, Loïc; Filleron, Thomas; Pradat, Yoann; Ducoulombier, Agnes; Pistilli, Barbara; Bachelot, Thomas; Viret, Frederic; Levy, Christelle; Signolle, Nicolas; Alfaro, Alexia; T. N. Tran, Diep; Judith Garberis, Ingrid; Talbot, Hugues; Christodoulidis, Stergios; Vakalopoulou, Maria; Droin, Nathalie; Stourm, Aurelie; Kobayashi, Maki; Kakegawa, Tomoya; Lacroix, Ludovic; Saulnier, Patrick; Job, Bastien; Deloger, Marc; Jimenez, Marta; Mahier, Celine; Baris, Vianney; Laplante, Pierre; Kannouche, Patricia; Marty, Virginie; Lacroix-Triki, Magali; Diéras, Veronique; André, Fabrice

doi:10.1038/s41591-023-02478-2

Public

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Shared by NobleBlocks on Jul 24, 2023 • 12:00 AM UTC

Authors:

Fernanda Mosele

Elise Deluche

Amelie Lusque

Abstract

Abstract The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing ( n = 72, cohort 1), HER2-low ( n = 74, cohort ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!